Galena Biopharma Inc (NASDAQ:GALE): What Oncologists Say About It?

1003

Dallas, Texas 02/20/2014 (FINANCIALSTRENDS) – Galena Biopharma Inc (NASDAQ:GALE) has been one of the leading pharmaceuticals which has invested in and has been successful in developing several candidates, which save patients who are suffering from cancer and are no longer responding to current range of cancer products.

Galena BiopharmaInc(NASDAQ:GALE)products which oncologists have evinced great interest in NeuVax, Abstral. GALE is known to develop vaccines which develop the immunity to strains of cancer causing cells. With Abstral GALE has introduced pain management focus to its portfolio.

According to oncologists, Abstral has been effective in helping cancer patients to bear and continue living their lives.  One of the main requirements in oncology treatment is keeping the pain out of cancer patients. Abstral, follows a rapid onset approach and brings pain relief. The advantage of this drug is that in situations and scenarios where pain management delivery is not possible intravenously or there is limited access to such services, Abstral has proved to be the most effective alternative. The value of the drug has been its ease of delivery of service and breakthrough in pain cancer patients always suffer from.

Galena BiopharmaInc(NASDAQ:GALE) suggest oncologists should extend the Phase 3 trial of NeuVax, especially for the subset analysis. This is not to deny the value of the current data which is impressive thus far. Oncologists that it does match the sterling standards that another cancer-fighting drug Alimta, an Eli Lilly product whose generic name is pemetrexed, which when it completed its Stage IV trials and proved to have highest efficacy in treatment of non-squamous cell cancer.

Galena BiopharmaInc(NASDAQ:GALE) with the subset analysis for NeuVax will see the statistics established and the opportunity to set up Phase III trial. However, this will be possible only if GALE is able to substantiate it current trial and hope that the trial proves to be positive.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.